Indivior Pharmaceuticals (INDV) Retained Earnings (2021 - 2026)

Indivior Pharmaceuticals' Retained Earnings history runs 6 years deep, the most recent figure standing at $165.0 million for Q1 2026.

• On a quarterly basis, Retained Earnings rose 571.43% year-over-year to $165.0 million in Q1 2026; TTM through Mar 2026 was $165.0 million, a 571.43% increase from a year earlier, with the FY2025 full-year figure at -$30.0 million, down 133.33% from the prior year.
• Retained Earnings rose to $165.0 million in Q1 2026 per INDV's latest filing, from -$30.0 million in the prior quarter.
• Across five years, Retained Earnings topped out at $1.3 billion in Q4 2022 and bottomed at -$346.0 million in Q3 2025.
• The 5-year median for Retained Earnings is -$31.5 million (2025), against an average of $103.2 million.
• Across the five-year window, Retained Earnings tumbled 133.33% in 2025 and soared 571.43% in 2026, its largest moves.
• Year by year, Retained Earnings stood at $1.3 billion in 2022, then tumbled by 122.1% to -$288.0 million in 2023, then jumped by 131.25% to $90.0 million in 2024, then plunged by 133.33% to -$30.0 million in 2025, then surged by 650.0% to $165.0 million in 2026.
• Per Business Quant, the three latest INDV Retained Earnings figures stand at $165.0 million (Q1 2026), -$30.0 million (Q4 2025), and -$346.0 million (Q3 2025).